ProfileGDS5678 / 1416157_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 86% 86% 84% 86% 88% 87% 87% 84% 88% 88% 85% 89% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.896489
GSM967853U87-EV human glioblastoma xenograft - Control 26.5182486
GSM967854U87-EV human glioblastoma xenograft - Control 36.5559686
GSM967855U87-EV human glioblastoma xenograft - Control 46.3703784
GSM967856U87-EV human glioblastoma xenograft - Control 56.6353286
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5882288
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5585487
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7001487
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1783384
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9234988
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.820488
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4415585
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0281289
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5511286